ALDXHealthcare · BiotechnologyALDX Stock Forecast: Aldeyra Therapeutics, Inc. Price Predictions for 2026-2027
The 6 Wall Street analysts covering Aldeyra Therapeutics, Inc. hold a median 12-month price target of $5 — +273.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 51 of 100 as at 10 Sept 2026 — in the upper half.
ALDX stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Aldeyra Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (92): The share count has been shrinking and the company is not leaning on new borrowing.
Momentum (4): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
ALDX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ALDX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +273.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 18 Mar 2026 | HC Wainwright & Co. | Downgrade | Neutral | $10 → $2.00 |
| 10 Nov 2025 | BTIG | Reiterates | Buy | — |
| 19 May 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Apr 2025 | BTIG | Maintains | Buy | — |
| 4 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 May 2024 | Oppenheimer | Reiterates | Outperform | — |
| 3 Apr 2024 | Oppenheimer | Upgrade | Outperform | — |
| 2 Apr 2024 | HC Wainwright & Co. | Reinstates | Buy | $10 |
| 17 Oct 2023 | Citigroup | Maintains | Buy | — |
| 17 Oct 2023 | Oppenheimer | Downgrade | Perform | — |
| 9 Aug 2023 | Oppenheimer | Reiterates | Outperform | — |
| 30 June 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 June 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 June 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 June 2023 | Citigroup | Maintains | Buy | — |
| 1 June 2023 | Citigroup | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ALDX appears on the weeks it earns a place.
ALDX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, Aldeyra Therapeutics, Inc. returned −75.9% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
ALDX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Aldeyra Therapeutics, Inc. (ALDX) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −2.6×
- Price / sales
- —
- Price / book
- 2.3×
- EV / EBITDA
- −1.9×
Cheaper than 86% of US stocks
Cheaper than 41% of US stocks
Cheaper than 71% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 32% of US stocks
Higher than 30% of US stocks
- Return on equity
- −49.5%
- Return on assets
- −22.7%
- Dividend yield
- —
Higher than 21% of US stocks
Higher than 18% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
Aldeyra Therapeutics, Inc. (ALDX) statistics: revenue, profit & scale
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Aldeyra Therapeutics, Inc. has a market value of $88.1M and an enterprise value of $45.5M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$23.1M.
Free cash flow in the twelve months to 30 June 2026: −$22.0M.
Trailing P/E: −2.6×; forward P/E: −5.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Aldeyra Therapeutics, Inc. employs 6 people.
Data provided by Twelve Data
ALDX vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Aldeyra Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about ALDX stock
What is the ALDX stock price forecast for 2026-2027?
The 6 Wall Street analysts covering Aldeyra Therapeutics, Inc. have a median 12-month price target of $5, with estimates ranging from $2 to $13. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ALDX stock a buy right now?
Of the 6 analysts covering Aldeyra Therapeutics, Inc., 5 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aldeyra Therapeutics, Inc. 51 out of 100 across roughly 4,600 US stocks as at 10 Sept 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ALDX?
As at 10 Sept 2026, Aldeyra Therapeutics, Inc. ranks 51 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (92 of 100).
Will ALDX stock go up?
No one can know that. What the data says: the median 12-month target from 6 analysts implies +273.1% from the last close, and Ticker Nerd's factor model ranks Aldeyra Therapeutics, Inc. 51 out of 100 as at 10 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ALDX stock forecast for 2030?
No analyst covering Aldeyra Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALDX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $13 over the next 12 months.
How has ALDX stock performed over the past year?
Aldeyra Therapeutics, Inc. returned -75.9% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Aldeyra Therapeutics, Inc. do?
Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering and developing therapies for immune-mediated diseases.
About Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering and developing therapies for immune-mediated diseases. Its current pipeline centers on small-molecule and related drug candidates for ophthalmology and other inflammatory conditions, including reproxalap for dry eye disease and allergic conjunctivitis, ADX-2191 for selected retinal disorders, and ADX-629 for several immune-related indications. The company also advances preclinical reactive aldehyde species modulator programs aimed at addressing systemic and retinal diseases. Aldeyra Therapeutics emphasizes treatments designed to modulate inflammatory pathways and improve patient care across eye disease, allergy, and broader immune-mediated segments. Based in Lexington, Massachusetts, Aldeyra Therapeutics operates as a clinical-stage biopharmaceutical developer with a portfolio positioned across multiple therapeutic areas and specialty markets.
CEO Dr. Todd C. Brady M.D., Ph.D. · 6 employees · United States · https://www.aldeyra.com